drugset
drugset / Trial / NCT06350006

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

NCT06350006 ↗

Phase 1 Recruiting 924 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study consists of two research phases: Phase Ib (includes dose escalation stage and efficacy expansion stage): To explore the safety, tolerability and initial efficacy of SHR-A1904 in the treatment of CLDN18.2-positive advanced solid tumors, and to determine the recommended dose and recommended population for the Phase III combination study. Phase III: A randomized, Open-Label, multicenter clinical study of SHR-A1904 combined with chemotherapy and immunotherapy Versus chemotherapy combined with immunotherapy for CLDN18.2-positive advanced solid tumors.

Timeline

Start
2024-05-29
Primary completion
2027-12-30
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-A1904 Unknown — —
Background Adebrelimab Monoclonal antibody — —
Background Capecitabine Small molecule — —
Background Oxaliplatin Small molecule — —

Indications

No indication recorded.